References
- Isobe K, Ejima Y, Tokumaru S, Shikama N, Suzuki G, Takemoto M, et al. Treatment of primary intraocular lymphoma with radiation therapy: A multi-institutional survey in Japan. Leuk Lymphoma 2006; 47: 1800–1805
- Nelson D F, Martz K L, Bonner H, Newall J, Kerman H D, Thompson J W, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23: 9–17
- Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
- Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
- Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R D, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862
- Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006; 107: 190–196
- Rubenstein J, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006
- Larocca L M, Capello D, Rinelli A, Nori S, Antinori A, Gloghini A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998; 92: 1011–1019
- Hegde U, Filie A, Little R F, Janik J E, Grant N, Steinberg S M, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105: 496–502
- Margolis L, Fraser R, Lichter A, Char D H. The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer 1980; 45: 688–692
- Hormigo A, Abrey L, Heinemann M H, DeAngelis L M. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 2004; 126: 202–208
- Smith J R, Rosenbaum J T, Wilson D J, Doalittle N D, Siegal T, Neuwelt E A, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002; 109: 1709–1716
- Batchelor T T, Kolak G, Ciordia R, Foster C S, Henson J W. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 2003; 9: 711–715
- Baumann M A, Ritch P S, Hande K R, Williams G A, Topping T M, Anderson T. Treatment of intraocular lymphoma with high-dose Ara-C. Cancer 1986; 57: 1273–1275
- Wong E T, Tishler R, Barron L, Wu J K. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004; 101: 139–145